Every 10-Q that Amneal Pharmaceuticals Inc (AMRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRX filings page.
Amneal Pharmaceuticals reported solid results for the three and six months ended June 30, 2026. Net revenue was $796,197 (in thousands) in Q2 2026 versus $724,508 (in thousands) a year earlier, and net income attributable to Amneal was $57,662 (in thousands) versus $22,417 (in thousands). For the first half, net revenue reached $1,518,716 (in thousands) and net income attributable to Amneal was $119,918 (in thousands). Diluted EPS was $0.18 in Q2 and $0.37 year-to-date. A very low effective tax rate of 1.9% in Q2 and 2.3% year-to-date supported bottom-line growth.
At June 30, 2026, Amneal held cash, cash equivalents and restricted cash of $139,619 (in thousands) and total assets of $3,776,348 (in thousands). Total debt was $2,684,263 (in thousands), primarily a Term Loan and Senior Notes due 2032, with interest expense, net of $108,404 (in thousands) for the first half. Operating cash flow swung to an outflow of $47,987 (in thousands), reflecting higher receivables, inventory builds and significant product-rights investments.
Strategically, Amneal is expanding through agreements including a $75,000 (in thousands) upfront payment to MSN for U.S. mirabegron rights, new tirzepatide and denosumab biosimilar arrangements, and a definitive deal to acquire Kashiv BioSciences for $375,000 (in thousands) in cash plus 28,942,108 shares and up to $350,000 (in thousands) in milestones and profit-based royalties. Legally, a Nationwide Opioids Settlement Agreement became effective, with total expected cash payments of $133.5 million through 2034 and naloxone product deliveries, and a $9,000 (in thousands) accrual was recorded for antitrust class action litigation.
Amneal Pharmaceuticals, Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $722.5 million from $695.4 million, while net income jumped to $78.0 million from $24.6 million. EPS for Class A shareholders increased to $0.20 basic versus $0.04 a year earlier as gross margin expanded, helped by lower cost of goods and reduced amortization.
The Specialty segment drove much of the growth with higher sales of CREXONT, BREKIYA autoinjector and UNITHROID, while Affordable Medicines also improved and AvKARE declined modestly. Amneal remains highly leveraged with $2.69 billion of term loans and senior notes and a stockholders’ deficiency of $46.0 million.
Cash, cash equivalents and restricted cash fell to $204.4 million from $312.9 million, partly due to $38.8 million of tax receivable agreement payments and initial opioid settlement installments. The company finalized its Nationwide Opioids Settlement Agreement and recorded approximately $79.3 million in related liabilities. After quarter-end, Amneal agreed to acquire Kashiv BioSciences for $375 million in cash, 28.9 million Class A shares and up to $350 million in contingent payments, and signed a major mirabegron supply and distribution deal with MSN Laboratories.
Amneal Pharmaceuticals (AMRX) reported Q3 2025 results. Net revenue was $784.5 million, up from $702.5 million a year ago. Operating income was $70.3 million versus $88.8 million. Net income attributable to Amneal was $2.4 million, or $0.01 per diluted share.
Performance by segment in Q3: Affordable Medicines $460.7 million, Specialty $125.2 million, and AvKARE $198.5 million. Year to date, net revenue reached $2.20 billion and operating income was $282.1 million, with diluted EPS of $0.11.
Results reflect a $31.4 million loss on refinancing, a $22.8 million intangible asset impairment tied to an FDA complete response letter dated July 22, 2025, and a tax benefit from the One Big Beautiful Bill Act that reduced current income tax liabilities by $23.5 million in Q3. Cash from operating activities for the first nine months was $209.7 million, with cash and cash equivalents of $201.2 million at September 30, 2025. Long‑term debt, net, was $2.57 billion.